A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension

Journal of Ocular Pharmacology and Therapeutics

Volumn 20, Issue 5, 2004, Pages 383-392

  Day, Douglas G ^a   Schacknow, Paul N ^b   Sharpe, Elizabeth D ^c   Ellyn, John C ^d   Kulze III, John C ^d   Threlkeld, Anisa B ^e   Jones, Evan D ^f   Brown, Reay H ^g   Jenkins, Jessica N ^h   Stewart, William C ⁱ  

^a Atlanta Research Company   (United States)

^b Visual Health and Surgical Center   (United States)

^c Charleston Research Company LLC   (United States)

^d Marietta Eye Clinic ^*

^e Carolina Eye Center   (United States)

^f Atlanta Oncology Associates   (United States)

^g Pharmaceutical Res Network LLC   (Greece)

^h UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ University of South Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; CARTEOLOL; LATANOPROST; LEVOBUNOLOL; METIPRANOLOL; TIMOLOL; TIMOLOL MALEATE;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BLEPHARITIS; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG SAFETY; ECONOMIC ASPECT; EYE BURNING; EYE IRRITATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PARALLEL DESIGN; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; VISUAL IMPAIRMENT;

ADRENERGIC BETA-ANTAGONISTS; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FEMALE; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OFFICE VISITS; PATIENT COMPLIANCE; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; SAFETY;

EID: 7444250645     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2004.20.383     Document Type: Article

References (20)

1. Spooner, J.J., Bullano, M.F., Ikeda, L.I., et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am. J. Manag. Care 8(suppl.):S262-S270, 2002.
2. Dasgupta, S., Oates, V., Bookhart, B.K., et al. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am. J. Manag. Care 8(suppl.):S255-S261, 2002.
3. Shaya, F.T., Mullins, C.D., Wong, W., et al. Discontinuation rates of topical glaucoma medications in a managed care population. Am. J. Manag. Care 8(suppl.):S271-S277, 2002.
4. Reardon, G., Schwartz, G.F., and Mozaffari, E. Patient persistency with ocular prostaglandin therapy: A population-based, retrospective study. Clin. Ther. 25:1172-1185, 2003.
5. Average Wholesale Price (AWP) Directory. MediSpan MDDB-SELECT. February 2001.
6. Stewart, W.C., Sine, C., Cate, E., et al. Daily cost of b-adrenergic blocker therapy. Arch. Ophthalmol. 115:853-856, 1997.
7. Stewart, W.C., Hudgins, A.C., Pruitt, C.A., et al. Daily cost of newer glaucoma agents. J. Ocular Pharmacol. Ther. 15:379-388, 1999.
8. Fiscella, R.G., Geller, J.L., Gryz, L.L., et al. Cost considerations of medical therapy for glaucoma. Am. J. Ophthalmol. 128:426-433, 1999.
9. State health plan schedule of allowances, Blue Cross and Blue Shield, Columbia, SC; 2001.
10. Pocock, S.J., Clayton, T.C., and Altman, D.G. Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls. Lancet 359:1686-1689, 2002.
11. Johnson, E.S., and Mozaffari, E. Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am. J. Manag. Care 8(suppl.):S249-S254, 2002.
12. Suzuki, Y., Shirato, S., Adachi, M., et al. Risk factors for the progression of treated primary open-angle glaucoma: A multivariate life-table analysis. Graefe's Arch. Clin. Exp. Ophthalmol. 237:463-467, 1999.
13. Book, S.A. Essentials of statistics. In: Arthur, A.A., Rogers, J.L., and Bradley, J.W., eds. Testing Statistical Hypotheses. New York: McGraw-Hill, 1978:117-122.
14. Mick, A.B., Gonzalez, S., Dunbar, M.T., et al. A cost analysis of the prostaglandin analogs. Optometry 73:614-619, 2002.
15. Vold, S.D., Riggs, W.L., and Jackimiec, J. Cost analysis of glaucoma medications: A 3-year review. J. Glaucoma 11:354-358, 2002.
16. Stewart, W.C., Leech, J., Sharpe, E.D., et al. An economic analysis of switching to latanoprost from a b-blocker or adding brimonidine or latanoprost to a b-blocker in open-angle glaucoma or ocular hypertension. Am. J. Manag. Care 8(suppl.):S240-S248, 2002.
17. Alm, A., Stjernschantz, J., and the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once-daily, evening or morning: A comparison with timolol. Ophthalmology 102:1743-1752, 1995.
18. Camras, C.B., and the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month, masked, multicenter trial in the United States. Ophthalmology 103:138-147, 1996.
19. Watson, P., Stjernschantz, J., and the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103:126-137, 1996.
20. Noecker, R.S., Dirks, M.S., Choplin, N.T., et al. A six-month, randomized, clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol. 135:55-63, 2003.